New Developments in the Management of Borderline Resectable Pancreatic Cancer
Abstract
The optimal management of borderline resectable pancreatic cancer remains unclear. Neoadjuvant chemoradiation remains the most common approach in the United States, while neoadjuvant chemotherapy alone is also widely utilized and has demonstrated efficacy but there has been no clear consensus about a regimen that would be most beneficial in this setting. We will discuss three abstracts that were presented in the 2013 ASCO Gastrointestinal Cancers Symposium in which various regimens were evaluated in the neoadjuvant setting.
Image: New sign at the entrance of Tufts Medical Center on the day of its renaming (March 4, 2008). (Wikimedia Commons)
Downloads
References
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. Jan-Feb;62(1):10-29.
Jonathan Ben Ashman, Adyr A Moss, Matthew D. Callister, Kunam S Reddy, David C Mulligan, Leonard L. Gunderson, Mitesh J. Borad. Neoadjuvant chemoradiation and intraoperative electron irradiation for locally unresectable/borderline resectable pancreas adenocarcinoma. J Clin Oncol. 2012;30, Suppl 4, Abstract 327.
Jose Mario Pimiento, Tai Hutchinson, Jill M. Weber, Manish R. Patel, Pamela Joy Hodul, Michael D. Chuong, et al. Multimodality therapy for borderline resectable pancreatic cancer: A single-institution experience. J Clin Oncol 2012. 2012;30, Suppl 4, Abstract 280.
Pavlos Papavasiliou, Jonathan R Piposar, Rodrigo Arrangoiz, Kathryn T Chen, Fang Zhu, Yun Shin Chun et al.. Margin status and neoadjuvant chemoradiation in patients with borderline resectable pancreatic cancer. J Clin Oncol. 2012;30, Suppl 4, Abstract 304.
Michael Chuong., Eric Albert Mellon, Sarah Hoffe, Ravi Shridhar, Gregory M. Springett, Pamela Joy Hodul, Mokenge Peter Malafa, Nicholas Figura, Barbara Centeno. Rates of pathologic complete or near complete response following neoadjuvant chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. J Clinic Oncol 2012. 2013;30, suppl 34, Abstract 221.
Taizo Hibi, Minoru Kitago, Koichi Aiura, Minoru Tanabe, Osamu Itano, Masahiro Shinoda, Yuta Abe, Hiroshi Yagi, Yuko Kitagawa. Phase I/II trial of neoadjuvant chemoradiotherapy with 5-FU, cisplatin, mitomycin C, and heparin for borderline resectable pancreatic cancer. J Clinic Oncology 2012. 2013;30, Suppl 34, Abstract 315.
Vincent J. Picozzi, Flavio G. Rocha, J. Bart Rose, L. William Traverso, Adnan Alseidi, Bruce S. Lin, Thomas A. Biehl, John A. Ryan, Ravi Moonka, Scott Helton. Extended neoadjuvant chemotherapy (CT)in borderline resectable pancreas cancer (BRPC): Is preoperative chemoradiation(CRT) essential?. J Clin Oncol 2012. 2013;30, Suppl 34, Abstract 236.
Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L, Linehan DC. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009 Jul;16(7):1727-33.
Springett GM, Hoffe SE. Borderline Resectable Pancreatic Cancer: On the Edge of Survival. Cancer Control 2008; 15(4):295-307.10. 1 [PMID 8813197]
Conroy T, Françoise Desseigne, M.D., Marc Ychou, M.D., Ph.D., Olivier Bouché, M.D., Ph.D., Rosine Guimbaud, M.D., Ph.D., Yves Bécouarn, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl J Med. 2011; 364(19): 1817 [ PMID 21561347]
Copyright (c) 2014 Jaya Sharma, John Ng, Martin D Goodman, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.